Yifan Pharmaceutical Co., Ltd. (SHE:002019)
China · Delayed Price · Currency is CNY 9.24
+0.05 (0.54%)
Oct 28, 2026, 3:04 PM CST
Yifan Pharmaceutical Financials Overview
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Revenue Revenue Growth | 4,932 | 5,133 | 5,160 | 4,068 | 3,837 | 4,409 |
Revenue Growth | -5.60% | -0.52% | 26.84% | 6.03% | -12.98% | -18.36% |
Gross Profit Gross Profit Growth | 2,245 | 2,376 | 2,414 | 1,929 | 1,853 | 1,815 |
Operating Income Operating Income Growth | 370.88 | 441.78 | 388.52 | 20.93 | 171.35 | 262.68 |
Net Income Net Income Growth | 311.21 | 402.02 | 385.97 | -551.07 | 191.22 | 278.4 |
Earnings Per Share EPS Growth | 0.26 | 0.33 | 0.32 | -0.45 | 0.15 | 0.23 |
EPS Growth | -24.60% | 3.13% | - | - | -34.78% | -70.89% |
Fiscal Year | FY 2025 |
|---|---|
| Period Ending | Dec '25 Dec 31, 2025 |
Pharmaceutical Products Division Pharmaceutical Products Division Growth | 4,367 |
Offset of Business Segment Offset of Business Segment Growth | -9.55 |
Pharmaceutical Raw Materials and Polymers Pharmaceutical Raw Materials and Polymers Growth | 775.05 |
Total Total Growth | 5,133 |
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Cash & Investments Cash & Investments Growth | 1,038 | 732.97 | 889.39 | 773.38 | 1,239 | 1,336 |
Total Debt Total Debt Growth | 2,959 | 2,363 | 2,294 | 1,995 | 2,177 | 2,274 |
Net Cash (Debt) Net Cash Growth | -1,921 | -1,630 | -1,405 | -1,222 | -937.51 | -937.76 |
Net Cash Growth | - | - | - | - | - | - |
Net Cash Per Share Net Cash Per Share Growth | -1.58 | -1.34 | -1.16 | -1.00 | -0.74 | -0.77 |
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Operating Cash Flow Operating Cash Flow Growth | 565.93 | 458.37 | 640.73 | 348.58 | 472.07 | 301.23 |
Capital Expenditures CapEx Growth | -593.27 | -559.23 | -628.16 | -504.09 | -542.27 | -571.74 |
Free Cash Flow Free Cash Flow Growth | -27.34 | -100.87 | 12.57 | -155.5 | -70.21 | -270.51 |
Free Cash Flow Growth | - | - | - | - | - | - |
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Gross Margin | 45.52% | 46.29% | 46.79% | 47.42% | 48.30% | 41.16% |
Operating Margin | 7.52% | 8.61% | 7.53% | 0.52% | 4.47% | 5.96% |
Pretax Margin | 6.55% | 8.25% | 7.53% | -21.36% | 4.09% | 4.78% |
Profit Margin | 6.31% | 7.83% | 7.48% | -13.55% | 4.98% | 6.31% |
FCF Margin | -0.55% | -1.97% | 0.24% | -3.82% | -1.83% | -6.13% |
Fiscal Year | Current | FY 2025 | FY 2024 |
|---|---|---|---|
| Period Ending | Oct '26 Oct 28, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 |
Dividend Per Share Dividend Per Share Growth | 0.100 | 0.100 | 0.200 |
Dividend Per Share Growth | -50.00% | -50.00% | - |
Dividend Yield | 1.08% | 0.84% | 1.87% |
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Oct '26 Oct 28, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
PE Ratio | 36.18 | 30.84 | 33.78 | - | 78.54 | 78.11 |
Forward PE | 27.18 | 20.36 | 20.82 | 33.59 | 16.33 | 32.78 |
P/FCF Ratio | - | - | 1037.05 | - | - | - |
PS Ratio | 1.93 | 2.42 | 2.53 | 4.43 | 3.92 | 4.93 |